Nutrition BioTech publishes Urolithin A COA guide for bulk buyers
Nutrition BioTech has released a production-route guide for bulk Urolithin A powder specifications and certificates of analysis, aimed at supplement brands and contract manufacturers comparing supplier documents. The company says U.S.-based ready stock is available with a 1 kg minimum order and lot-specific COAs shipped with every order.
Why it matters: - Bulk Urolithin A buyers often need to compare more than assay numbers when vetting suppliers. - Production route can change the impurity profile, which affects quality review, documentation checks and supplier comparisons. - The guide is designed for purchasing and quality teams at supplement brands and contract manufacturers.
What happened: - Nutrition BioTech (NaturalBestBio) published a technical guide on bulk Urolithin A powder specifications and certificates of analysis, organized by production route. - The guide covers both chemical synthesis and fermentation routes for Urolithin A, CAS 1143-70-0. - The company also published buyer resources for the guide and product specifications, including the production-route guide and product specifications and sample requests.
The details: - Most specification sheets list an assay figure such as 98% by HPLC, but that alone does not describe the remaining material. - The guide says synthesis-route Urolithin A can contain route-specific residues, including a synthesis intermediate, copper from the catalyst, aluminum and named process solvents. - The guide says fermentation-route material raises different quality questions, including residual ellagic acid and related urolithins. - The guide says buyers should check identity by a structural method such as ¹H NMR or LC-MS, not by HPLC retention time alone. - The guide says a proper COA should state the HPLC assay method and reference standard. - The guide says buyers should look for route-specific impurities, numeric limits for lead, cadmium, arsenic and mercury, individually named residual solvents, microbiology, loss on drying, appearance, lot number, test dates and the issuing laboratory. - Nutrition BioTech says its Urolithin A powder is assayed at not less than 98.0% by HPLC and identified by HPLC and ¹H NMR. - Nutrition BioTech says the supplied material can be either synthesis-based or fermentation-based, and the production route is stated in the product documentation. - Nutrition BioTech says ready stock is held in the United States, with a 1 kg minimum order. - Nutrition BioTech says the product ships in 20 kg fiber drums with inner plastic bags and dispatch occurs within 3 working days of purchase order. - Nutrition BioTech says its quality system includes ISO 22000:2018, FSSC 22000 and HACCP, with certificates available on request. - Nutrition BioTech says every lot ships with a lot-specific Certificate of Analysis, and the public specification sheet is not a batch COA. - Nutrition BioTech says lot COAs and supporting records are available for qualified buyer review before purchase.
Between the lines: - The guide reflects a broader shift in bulk ingredient buying toward documentation that matches the production route, not just a headline purity number. - For procurement teams, the practical issue is whether a supplier can show what is in the remaining fraction of the material. - The emphasis on route-specific testing also suggests buyers are being pushed to ask for more complete COAs before approval.
What's next: - Buyers can review the route-specific guide and request product specifications or samples through Nutrition BioTech's published links. - Nutrition BioTech is positioning lot-level COAs and supporting records as part of its pre-purchase review process for qualified buyers. - The company says its sales team can be reached at +1 909-745-1357 for B2B inquiries.
The bottom line: - Nutrition BioTech is using a route-specific COA guide to make bulk Urolithin A buying more transparent for technical procurement teams.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
World Healthcare Report
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.